Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,600 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $19.99, for a total value of $171,914.00. Following the completion of the transaction, the chief executive officer now directly owns 743,675 shares in the company, valued at $14,866,063.25. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Atara Biotherapeutics Inc (NASDAQ ATRA) traded up $2.00 during midday trading on Friday, reaching $29.50. The company had a trading volume of 1,241,175 shares, compared to its average volume of 1,203,030. Atara Biotherapeutics Inc has a one year low of $11.80 and a one year high of $30.90. The stock has a market cap of $1,033.89, a PE ratio of -8.50 and a beta of 1.27.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). equities analysts predict that Atara Biotherapeutics Inc will post -4 EPS for the current year.
ATRA has been the topic of a number of analyst reports. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Jefferies Group reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Finally, Goldman Sachs Group reissued a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a report on Friday, October 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $30.60.
A number of large investors have recently added to or reduced their stakes in ATRA. SG Americas Securities LLC bought a new stake in Atara Biotherapeutics in the 3rd quarter worth approximately $142,000. Voya Investment Management LLC increased its stake in Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Atara Biotherapeutics in the 3rd quarter worth approximately $170,000. State of Wisconsin Investment Board bought a new stake in Atara Biotherapeutics in the 2nd quarter worth approximately $252,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after purchasing an additional 1,369 shares during the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/20/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-8600-shares.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.